Biotech News
Lineage Announces Acquisition of NeuroAirmid Therapeutics and Clinical Stage Program for the Treatment of Huntington’s Disease
Human Neural Stem Cell Transplants Offer a Novel Approach to Treating Huntington’s Disease Acquisition Includes Rights Relating to a Stem Cell-Derived Clinical Trial for Huntington’s Disease (REGEN4HD), a Phase 1b/2a Clinical Trial Currently Enrolling Patients NeuroAirmid Shareholders Received $4.7
